A distributor arrangement that pays a wound care practice, or its staff, based on the volume or size of the skin substitute product ordered is now one of the most closely examined fact patterns in federal healthcare enforcement. In December 2025, the Department of Justice secured a $309 million False Claims Act settlement from the owners of Apex Medical LLC, whose skin graft business grew on commissions and rebates a wholesale distributor paid for every graft ordered, regardless of the wound's size. A practice that accepts a rebate or marketing allowance tied to distributor purchase volume carries the same Anti-Kickback Statute exposure, whether or not the arrangement was ever designed as fraud.
The Kickback Theory Behind Distributor Commissions
The federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)) prohibits paying or accepting anything of value to induce the purchase of an item reimbursed by a federal healthcare program. A distributor commission, rebate, or pricing spread paid to a practice based on the volume or size of the product ordered is remuneration tied to a federal-program purchase decision, satisfying the theory without proof that any individual graft was medically unnecessary. Under 42 U.S.C. § 1320a-7b(g), a claim resulting from a kickback-tainted purchase is a false claim, which is why DOJ pursues these arrangements as False Claims Act cases, not standalone kickback violations.
The Apex Medical Case: Commissions Tied to Graft Size
Apex Medical owners Alexandra Gehrke and Jeffrey King agreed to pay a combined $309 million civil settlement, after a scheme DOJ traced from November 2022 through May 2024. The distributor paid the owners hundreds of millions of dollars in kickbacks, often structured as non-compliant rebates, in exchange for graft orders, and the owners in turn paid sales representatives commissions tied to the number and size of the grafts generated, tens of millions more in downstream kickbacks. DOJ calculated roughly $1.2 billion in resulting false claims, with federal programs paying out $614,945,420 before the scheme stopped. Both were sentenced in October 2025 to over 14 years each on the criminal side of the same conduct.
The Pricing Spread CMS Just Eliminated
Through 2025, Medicare reimbursed most skin substitutes at a rate tied to average sales price, letting a distributor or provider buy low and bill high, retaining the spread. HHS-OIG reported in September 2025 that the spread helped drive Medicare Part B spending on these products from under $400 million in 2022 to over $10 billion in 2024. Effective January 1, 2026, CMS replaced that formula with a flat $127.14 per square centimeter rate under the CY2026 Medicare Physician Fee Schedule final rule (CMS-1832-F), projected to cut 2026 spending on these products by roughly $19.6 billion. The new rate removes the spread going forward, but not for purchases and claims made under the old formula, which remain inside the government's six-year False Claims Act lookback.
What This Means for Wound Care Providers
A practice that buys skin substitutes through a distributor should treat any commission, rebate, or free product tied to purchase volume as an Anti-Kickback Statute question, separate from whether the product was medically necessary or properly billed. Documented medical necessity and clean local coverage determination compliance, covered in Wound Care LCD Compliance: Coverage Criteria by Documentation Element, do not resolve a purchase relationship carrying prohibited remuneration. CMS has paired the rate cut with expanded prepayment review of skin substitute claims, so the distributor relationship and the billing pattern are now both likely to draw scrutiny in the same matter.
A commission or rebate tied to how many grafts a distributor sells, or how large each graft is, is remuneration tied to a federal healthcare program purchase decision. Whether the wound care itself was medically necessary is a separate question the kickback theory does not depend on.
Why Early Legal Counsel Is Critical
It is critical that wound care providers promptly retain experienced healthcare defense counsel before signing a distributor agreement, upon learning that a distributor relationship includes rebates or commissions tied to volume, or upon receiving a subpoena or other government inquiry touching skin substitute purchasing. Early legal intervention can protect the practice's rights, ensure the arrangement is reviewed against the Anti-Kickback Statute before it becomes the subject of an investigation, and let counsel communicate with investigators on the practice's behalf. Delaying representation can significantly affect the outcome.
How Health Law Alliance Can Help
Health Law Alliance defends wound care providers against skin substitute enforcement, from reviewing a distributor arrangement before it is signed through defending an Anti-Kickback Statute investigation once one has opened. Our bench includes a former federal prosecutor and attorneys who have represented providers in CMS program-integrity reviews of wound care billing. If your practice has a distributor arrangement you want reviewed, or has received an inquiry touching skin substitute purchasing, contact us for a free, confidential consultation.
